| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/18/2010 | US20100040688 Hydrogel microparticle formation in aqueous solvent for biomedical applications |
| 02/18/2010 | US20100040687 Tissue Scaffolds |
| 02/18/2010 | US20100040686 Biomaterial |
| 02/18/2010 | US20100040685 Collagen-based matrix for use as restorative material, and method for preparing the same |
| 02/18/2010 | US20100040684 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 02/18/2010 | US20100040683 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 02/18/2010 | US20100040682 Fenofibrate tablets |
| 02/18/2010 | US20100040681 Oral Sustained-Release Triple Layer Tablet |
| 02/18/2010 | US20100040680 Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation |
| 02/18/2010 | US20100040679 Compositions for Reducing Nicotine Withdrawal Symptoms and/or Tobacco Usage |
| 02/18/2010 | US20100040678 Organic compounds |
| 02/18/2010 | US20100040677 Formulations for benzimidazolyl pyridyl ethers |
| 02/18/2010 | US20100040676 Polycistronic hiv vector constructs |
| 02/18/2010 | US20100040675 Compositions and methods for promoting or inhibiting angiogenesis |
| 02/18/2010 | US20100040674 Controlled delivery of bioactive agents from decomposable films |
| 02/18/2010 | US20100040673 Hygiene tissue comprising a microbe-inhibiting composition |
| 02/18/2010 | US20100040672 Delivery of therapeutics |
| 02/18/2010 | US20100040668 Biomimetic Hydroxyapatite Composite Materials and Methods for the Preparation Thereof |
| 02/18/2010 | US20100040664 Aabb-poly(depsipeptide) biodegradable polymers and methods of use |
| 02/18/2010 | US20100040662 Fixation Devices For Tissue Repair |
| 02/18/2010 | US20100040660 Development of a tissue - engineered scaffold for nerve regeneration using a biocompatible and injectable hydrogel |
| 02/18/2010 | US20100040656 Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them |
| 02/18/2010 | US20100040653 Intercalated layered silicate |
| 02/18/2010 | US20100040580 Freeze-dried composition of inactivated virus envelope with membrane fusion activity |
| 02/18/2010 | US20100040564 Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents |
| 02/18/2010 | US20100040563 Solubilization of Cyclohexane-Based Carboxamide Derivatives for Use as Sensates in Consumer Products |
| 02/18/2010 | US20100040562 Novel composition |
| 02/18/2010 | US20100040561 Penetrating pharmaceutical foam |
| 02/18/2010 | US20100040560 Aerosolized fluoroquinolones and uses thereof |
| 02/18/2010 | US20100040559 Use of a Pharmaceutical Composition Comprising an Anticholinergic for Killing Microorganisms and for Treating Respiratory Tract Infections |
| 02/18/2010 | US20100040558 Green tea polyphenol alpha secretase enhancers and methods of use |
| 02/18/2010 | US20100040557 Double-layered zaleplon- contained tablet |
| 02/18/2010 | US20100040556 Carrier nanoparticles and related compositions, methods and systems |
| 02/18/2010 | US20100040555 Magnetic Nanoparticles Compositions and Uses Thereof |
| 02/18/2010 | US20100040549 Composition for Targeted Drug Delivery and Controlled Release |
| 02/18/2010 | US20100040538 Polymer Systems for Lung Volume Reduction Therapy |
| 02/18/2010 | US20100037890 Aerosolized fluoroquinolones and uses thereof |
| 02/18/2010 | DE102008037324A1 Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung A pharmaceutical formulation for pulmonary blood pressure reduction |
| 02/18/2010 | CA2735562A1 Organic compounds for wound healing |
| 02/18/2010 | CA2734200A1 An extracorporeal cell-based therapeutic device and delivery system |
| 02/18/2010 | CA2734095A1 Coated tablets with a remaining degradation surface over the time |
| 02/18/2010 | CA2734075A1 Pharmaceutical compositions configured to deter dosage form splitting |
| 02/18/2010 | CA2734060A1 Method of standardization of injectable medicines and their diluents |
| 02/18/2010 | CA2733963A1 Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsions |
| 02/18/2010 | CA2733959A1 Nanocrystal nano-emulsion |
| 02/18/2010 | CA2733787A1 Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders |
| 02/18/2010 | CA2733727A1 Intravaginal devices with a rigid support, methods of making, and uses thereof |
| 02/18/2010 | CA2733724A1 Mucoadherents compositions and their use |
| 02/18/2010 | CA2733651A1 Pharmaceutical formulation for reducing pulmonary blood pressure |
| 02/18/2010 | CA2733611A1 Pharmaceutical compositions with modified release properties comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| 02/18/2010 | CA2733509A1 Antimicrobial silver solutions |
| 02/18/2010 | CA2732931A1 Amorphous ambrisentan |
| 02/18/2010 | CA2732892A1 Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration |
| 02/18/2010 | CA2731473A1 Carrier system for biological agents containing organosilicon compounds and uses thereof |
| 02/18/2010 | CA2731353A1 Stable injectable oil-in-water docetaxel nanoemulsion |
| 02/18/2010 | CA2731316A1 Pharmaceutical compositions |
| 02/18/2010 | CA2730716A1 Composite particles having an antioxidant-based protective system, and topical compositions comprising the same |
| 02/17/2010 | EP2154160A1 Hydroxyalkyl starch derivatives |
| 02/17/2010 | EP2153863A1 Method of coating microneedle |
| 02/17/2010 | EP2153850A1 Liquid compositions comprising dextran, in situ formed implants obtained thereof |
| 02/17/2010 | EP2153849A2 Contraception process and administration form for the same |
| 02/17/2010 | EP2153838A1 Anti-norovirus agent, and composition comprising the same |
| 02/17/2010 | EP2153834A2 Extended release pharmaceutical compositions comprising quetiapine salts |
| 02/17/2010 | EP2153828A2 Composition for the Transdermal Delivery of Fentanyl |
| 02/17/2010 | EP2153827A2 Composition for the Transdermal Delivery of Fentanyl |
| 02/17/2010 | EP2153826A2 Nanoparticles comprising a cyclodextrin and a biologically active molecule and uses thereof |
| 02/17/2010 | EP2153825A1 Therapeutic formulation for administering tolterodine with controlled release |
| 02/17/2010 | EP2153824A1 Seamless multiparticulate formulations |
| 02/17/2010 | EP2153823A1 Double-layered zaleplon-containing tablet |
| 02/17/2010 | EP2153822A1 Granulation of active pharmaceutical ingredients |
| 02/17/2010 | EP2153821A1 Oral formulations of camptothecin derivatives |
| 02/17/2010 | EP2153820A1 Liposome and method for producing liposome |
| 02/17/2010 | EP2153819A2 Compositions containing therapeutically active components having enhanced solubility |
| 02/17/2010 | EP2153732A1 Production of Beadlets Comprising Hygroscopic Plant Extracts |
| 02/17/2010 | EP2152320A2 Encapsulated contrast agents |
| 02/17/2010 | EP2152313A1 Oral nicotine formulation buffered with amino acid |
| 02/17/2010 | EP2152312A1 Low-viscous anthracycline formulation |
| 02/17/2010 | EP2152304A1 Nanoemulsion therapeutic compositions and methods of using the same |
| 02/17/2010 | EP2152288A1 Reconstituted surfactants having improved properties |
| 02/17/2010 | EP2152268A1 Method of treating diabetes |
| 02/17/2010 | EP2152251A2 Increased drug loading capacity of polymeric material |
| 02/17/2010 | EP2152250A1 Solid dosage forms comprising an enteric coating with accelerated drug release |
| 02/17/2010 | EP2152249A1 Oral dosage form providing fast absorption of drug |
| 02/17/2010 | EP2152248A2 Controlled release tablet formulation containing magnesium aluminometasilicate |
| 02/17/2010 | EP2152247A1 Anti-insomnia compositions and methods |
| 02/17/2010 | EP2152245A2 Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| 02/17/2010 | EP2152244A2 Oral delivery of proteins and peptides |
| 02/17/2010 | EP2152243A2 Highly concentrated insulin solutions and compositions |
| 02/17/2010 | EP2152242A1 Pest control formulation |
| 02/17/2010 | EP2152241A1 Method of delivering a protein into a cell |
| 02/17/2010 | EP2152239A1 Stable oxaliplatin composition for parenteral administration |
| 02/17/2010 | EP2152238A2 Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| 02/17/2010 | EP2152237A1 Novel pharmaceutical composition |
| 02/17/2010 | EP2152236A1 Pharmaceutical composition of an anthracycline |
| 02/17/2010 | EP2152235A2 Aqueous aerosol preparations containing therapeutically active micro-organisms or parts of micro-organisms and method for producing corresponding aerosols |
| 02/17/2010 | EP2152234A1 Lyophilized pharmaceutical compositions and methods of making and using same |
| 02/17/2010 | EP2152233A1 High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant |
| 02/17/2010 | EP2152232A1 Methods and compositions for administration of oxybutynin |
| 02/17/2010 | EP2152227A1 A liquid formulation for administering nicotine |
| 02/17/2010 | EP2152195A1 Peptide pharmaceutical for oral delivery |